Variante “Delta” del COVID-19: ¿Por qué debemos preocuparnos?

Joshuan J. Barboza

doi:10.35839/repis.5.3.1128

Autores/as

Joshuan J. Barboza Escuela de Medicina, Universidad Señor de Sipán, Chiclayo, Perú; Tau-Relaped Group, Trujillo, Perú https://orcid.org/0000-0002-2896-1407

DOI:

https://doi.org/10.35839/repis.5.3.1128

Descargas

Los datos de descarga aún no están disponibles.

Referencias

Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021;397(10292):2331-3. doi:10.1016/s0140-6736(21)01290-3.

Lustig Y, Zuckerman N, Nemet I, Atari N, Kliker L, Regev-Yochay G, et al. Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel. Euro Surveill. 2021;26(26). doi:10.2807/1560-7917.Es.2021.26.26.2100557.

Lazarevic I, Pravica V, Miljanovic D, Cupic M. Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far? Viruses. 2021;13(7). doi:10.3390/v13071192.

Liu J, Liu Y, Xia H, Zou J, Weaver SC, Swanson KA, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021. doi:10.1038/s41586-021-03693-y.

Focosi D, Tuccori M, Baj A, Maggi F. SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. Viruses. 2021;13(7). doi:10.3390/v13071211.

Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveill. 2021;26(24). doi:10.2807/1560-7917.Es.2021.26.24.2100509.